J.P. Morgan Chase & Co. is out with a research report on Gilead Sciences GILD and is adding it to the Focus List. It has an Overweight rating and a $50 price target on shares.
In a note to clients, J.P. Morgan Chase & Co. writes, "We are adding Gilead to the J.P. Morgan Analyst Focus List and retaining our Dec 2012 PT of $50 (34% upside from current levels). GILD shares haven't recovered from recent market volatility despite two fundamentally de-risking events (Complera approval last week, positive QUAD phase 3 data yesterday). In our view, current valuation (~30% discount to peers at 8X) doesn't reflect the opportunity from the QUAD (launching late 2012) or Complera (already launched)."
Shares of GILD lost 16 cents yesterday to close at $37.27.
Market News and Data brought to you by Benzinga APIs© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
date | ticker | name | Price Target | Upside/Downside | Recommendation | Firm |
---|
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in